Pharmaceutical

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.

Feb 2, 2024 - 18:00
BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales
Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
Read the original article

Tags:

Previous Article

We’re naming cancers all wrong, oncology leader says

Next Article

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Private equity deals in pharmaceutical in Germany incre...

Jul 31, 2023

STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud

STAT+: Former medical device CEO who sold dummy, plasti...

Mar 8, 2024

STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more

STAT+: Pharmalittle: We’re reading about a pharma job s...

Feb 23, 2024